Abstract: An scFv-Fc dimer binds and neutralizes TGF?1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGF?1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
Abstract: The present invention encompasses ophthalmic compositions that may be used for various conditions of the eye, and particularly, conditions of the cornea. Also encompassed are methods that utilise these compositions and kits that include these compositions.
Type:
Grant
Filed:
October 23, 2020
Date of Patent:
March 26, 2024
Assignee:
Auckland Uniservices Limited
Inventors:
Colin Green, Carol Ann Greene, Trevor Sherwin
Abstract: The invention relates to proteins having multi-specific binding abilities by fusion of an OB-fold variant, in particular from the Sac7d family, to the light or heavy chain of an antibody.
Type:
Grant
Filed:
November 13, 2018
Date of Patent:
March 19, 2024
Assignee:
AFFILOGIC
Inventors:
Olivier Kitten, Mathieu Cinier, Simon Huet
Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
Type:
Grant
Filed:
April 1, 2020
Date of Patent:
February 27, 2024
Assignee:
BIOMARIN PHARMACEUTICAL INC.
Inventors:
Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O. Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap
Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.
Abstract: Provided are methods for promoting the healing of injuries to tendons and ligaments by administering a NELL1 protein or a nucleic acid encoding a NELL1 protein to a subject in need thereof. Also provided are NELL1 compositions and methods for promoting tissue regeneration, promoting the healing of wounds, and enhancing fibroblast migration, proliferation, or both migration and proliferation.
Abstract: The present disclosure relates to a pharmaceutical composition for treating, preventing and/or ameliorating spinal muscular atrophy (SMA) and a method of administration thereof. A pharmaceutical composition for treating, preventing and/or ameliorating SMA according to an embodiment of the present disclosure may comprise a SMN protein, which is the cause of the onset of SMA. The pharmaceutical composition may be administered directly to a subject suffering from SMA via intracerebroventricular, intrathecal or intra-cisterna magna administration, thereby treating or preventing SMA or ameliorating symptoms of SMA. The pharmaceutical composition for treating, preventing or ameliorating SMA according to one embodiment of the present disclosure is safe, cost-effective and/or accessible compared to other previously approved drugs and can achieve substantially equivalent therapeutic effects.
Abstract: The present disclosure describes the C-type lectin CLEC11a as a bone growth factor. Clec11a-deficient mice showed reduced bone volume and mineralization, while bone resorption remained unchanged. Administration of recombinant Clec11a systemically promoted bone formation in mice at risk for osteoporosis.
Type:
Grant
Filed:
May 1, 2020
Date of Patent:
February 6, 2024
Assignee:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.
Type:
Grant
Filed:
August 22, 2022
Date of Patent:
January 30, 2024
Assignees:
TG Therapeutics, Inc., Laboratoire Francais du Fractionnement et des Biotechnologies
Inventors:
George Costas Avgerinos, Patrick Michael Hossler, Jill A. Myers, Yune Z. Kunes
Abstract: The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), fibrosis, and/or pulmonary hypertension.
Abstract: A polypeptide having a heavy chain variable region and/or a light chain variable region that specifically binds to Ror2 protein, as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region, are provided. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.
Type:
Grant
Filed:
November 23, 2021
Date of Patent:
January 23, 2024
Assignee:
BIOATLA, INC.
Inventors:
Jay M. Short, Hwai Wen Chang, Gerhard Frey
Abstract: The invention relates to the treatment of bone disorders. In particular, the invention provides an approach involving administration of a high initial dose or doses of an sclerostin antibody to bring about a rapid increase in bone formation, followed by administration of lowers doses of the antibody to give a sustained lower rate of bone formation after the initial burst of bone formation. The invention also provides an approach involving decreasing dosing frequency with such an antibody to control bone formation. The approaches may be used in particular in those subjects who would benefit most from such an initial rapid burst of bone formation. Examples of such subjects include subjects who have been recently diagnosed or are experiencing severe symptoms of the disorder, as well as those subjects who have been administered a different treatment for the bone disorder which is proving ineffective. The approaches may be used in combination with each other.
Type:
Grant
Filed:
December 11, 2015
Date of Patent:
December 26, 2023
Assignees:
AMGEN INC., UCB PHARMA S.A.
Inventors:
Martyn Kim Robinson, Michael Stuart Ominsky, Xiaodong Li, Hua Zhu Ke
Abstract: A modified IgG antibody binds and neutralizes TGF?1 selectively and with high affinity and avidity. The modified IgG antibody comprises four polypeptide chains and may comprise modifications to the elbow regions of the polypeptide chains. The modified IgG antibody may comprise the same VH and VL domains or CDR regions as metelimumab. The modified IgG anti-body is useful in therapeutic and diagnostic applications.
Abstract: The present disclosure relates to a self-assembled nanostructure of an elastin- and resilin-based block copolypeptide with stimuli responsiveness and resilience for drug delivery, tissue engineering and regenerative medicine, a method for preparing the same and application thereof. The diblock polypeptide reversibly forms a self-assembled micelle structure in response to temperature stimuli and a hydrogel prepared using the triblock polypeptide undergoes reversible sol-gel or gel-sol transition in response to temperature stimuli and exhibits enhanced mechanical strength due to chemical crosslinkages between tyrosine residues. With such superior properties, the diblock/triblock polypeptide of the present disclosure can be used for drug delivery systems, scaffolds for tissue engineering and kits for tissue or organ regeneration.
Type:
Grant
Filed:
March 23, 2017
Date of Patent:
November 28, 2023
Assignee:
Industry-University Cooperation Foundation Hanyang University Erica Campus
Inventors:
Dong Woo Lim, Aamna Basheer, Jae Sang Lee, Min Jung Kang
Abstract: Novel compositions for treating wounds and promoting the healing thereof are described, including composition containing novel combinations of a carrier and recombinant platelet derived grown factor having fewer isoforms and enhanced biostability. Methods of treating wounds with novel therapeutic composition using dosing procedures leading to effective results with a minimal number of treatment applications are also described.
Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a prolonged activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.
Type:
Grant
Filed:
June 19, 2020
Date of Patent:
November 14, 2023
Assignees:
Institut National de la Sante et de la Recherche Medicale, Université Paul Sabatier Toulouse III
Abstract: The invention relates to novel methods, uses and compositions for the prophylaxis or the treatment of osteoarthritis, and conditions associated therewith.
Type:
Grant
Filed:
February 8, 2018
Date of Patent:
October 31, 2023
Assignee:
ANNEXIN PHARMACEUTICALS AB
Inventors:
Johan Frostegård, Anna Frostegård, Divya Thiagarajan
Abstract: The invention relates to neutralizing antibodies of GM-CSF and compositions comprising the same for use in the treatment of inflammatory disorders such as rheumatoid arthritis according to specific dosing regimen. The invention relates also to neutralizing antibodies of GM-CSF and compositions comprising the same for use in the treatment of pain, e.g. pain experienced in inflammatory disorders such as rheumatoid arthritis, according to specific dosage regimen.
Type:
Grant
Filed:
August 17, 2020
Date of Patent:
October 24, 2023
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Thomas Wagner, Malin Carlsson, Margit Staum Kaltoft
Abstract: The present disclosure provides compositions and methods for targeted delivery of therapeutic agents. The present disclosure further provides methods for treating or preventing the metastasis or recurrence of a cancer using platelets loaded with a therapeutic agent (for example, an immunotherapeutic agent).
Abstract: The present disclosure relates to the field of laboratory diagnostics. Specifically, means and methods are disclosed for determining a patient's risk of suffering from acute kidney injury after a surgical procedure based on the detection of GDF-15, troponin T and/or a natriuretic peptide.
Type:
Grant
Filed:
November 26, 2019
Date of Patent:
August 8, 2023
Assignee:
Roche Diagnostics Operations, Inc.
Inventors:
Andrea Horsch, Dietmar Zdunek, Georg Hess